Search research articles
Contact Us
Filters
Showing results (21-30 of 68) with videos related to
Page
of 7
Sort By:
The Journal of Infectious Diseases
|
February 1, 2022
Balancing Statistical Power and Risk in HIV Cure Clinical Trial Design
Jillian S Y Lau, Deborah Cromer, Mykola Pinkevych, et al.
Journal of Virus Eradication
|
November 9, 2019
Fimepinostat, a novel dual inhibitor of HDAC and PI3K, effectively reverses HIV-1 latency <i>ex vivo</i> without T cell activation
Jesper D Gunst, Kathrine Kjær, Rikke Olesen, et al.
BMC Infectious Diseases
|
October 6, 2011
Evaluation of cardiovascular biomarkers in HIV-infected patients switching to abacavir or tenofovir based therapy
Thomas A Rasmussen, Martin Tolstrup, Jesper Melchjorsen, et al.
Pathology
|
July 1, 2022
Factors associated with weak positive SARS-CoV-2 diagnosis by reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR)
Priyank Rawat, Jennifer M Zerbato, Ajantha Rhodes, et al.
Journal of Virology
|
November 10, 2017
Estimating Initial Viral Levels during Simian Immunodeficiency Virus/Human Immunodeficiency Virus Reactivation from Latency
Mykola Pinkevych, Christine M Fennessey, Deborah Cromer, et al.
AIDS (London, England)
|
March 5, 2019
In-vivo administration of histone deacetylase inhibitors does not impair natural killer cell function in HIV+ individuals
Carolina Garrido, Martin Tolstrup, Ole S Søgaard, et al.
AIDS (London, England)
|
March 9, 2017
Romidepsin-induced HIV-1 viremia during effective antiretroviral therapy contains identical viral sequences with few deleterious mutations
Anni Winckelmann, Kirston Barton, Bonnie Hiener, et al.
Plos One
|
April 6, 2012
Comparison of bone and renal effects in HIV-infected adults switching to abacavir or tenofovir based therapy in a randomized trial
Thomas A Rasmussen, Danny Jensen, Martin Tolstrup, et al.
Open Forum Infectious Diseases
|
June 3, 2015
Activation of latent human immunodeficiency virus by the histone deacetylase inhibitor panobinostat: a pilot study to assess effects on the central nervous system
Thomas A Rasmussen, Martin Tolstrup, Holger Jon Møller, et al.
Plos One
|
May 3, 2013
Administration of a Toll-like receptor 9 agonist decreases the proviral reservoir in virologically suppressed HIV-infected patients
Anni A Winckelmann, Lærke V Munk-Petersen, Thomas A Rasmussen, et al.
Page
of 7
Search research articles
Search
Showing results (21-30 of 68) with videos related to
Sort By:
Page
of 7
The Journal of Infectious Diseases
|
February 1, 2022
Balancing Statistical Power and Risk in HIV Cure Clinical Trial Design
Jillian S Y Lau, Deborah Cromer, Mykola Pinkevych, et al.
Journal of Virus Eradication
|
November 9, 2019
Fimepinostat, a novel dual inhibitor of HDAC and PI3K, effectively reverses HIV-1 latency <i>ex vivo</i> without T cell activation
Jesper D Gunst, Kathrine Kjær, Rikke Olesen, et al.
BMC Infectious Diseases
|
October 6, 2011
Evaluation of cardiovascular biomarkers in HIV-infected patients switching to abacavir or tenofovir based therapy
Thomas A Rasmussen, Martin Tolstrup, Jesper Melchjorsen, et al.
Pathology
|
July 1, 2022
Factors associated with weak positive SARS-CoV-2 diagnosis by reverse transcriptase-quantitative polymerase chain reaction (RT-qPCR)
Priyank Rawat, Jennifer M Zerbato, Ajantha Rhodes, et al.
Journal of Virology
|
November 10, 2017
Estimating Initial Viral Levels during Simian Immunodeficiency Virus/Human Immunodeficiency Virus Reactivation from Latency
Mykola Pinkevych, Christine M Fennessey, Deborah Cromer, et al.
AIDS (London, England)
|
March 5, 2019
In-vivo administration of histone deacetylase inhibitors does not impair natural killer cell function in HIV+ individuals
Carolina Garrido, Martin Tolstrup, Ole S Søgaard, et al.
AIDS (London, England)
|
March 9, 2017
Romidepsin-induced HIV-1 viremia during effective antiretroviral therapy contains identical viral sequences with few deleterious mutations
Anni Winckelmann, Kirston Barton, Bonnie Hiener, et al.
Plos One
|
April 6, 2012
Comparison of bone and renal effects in HIV-infected adults switching to abacavir or tenofovir based therapy in a randomized trial
Thomas A Rasmussen, Danny Jensen, Martin Tolstrup, et al.
Open Forum Infectious Diseases
|
June 3, 2015
Activation of latent human immunodeficiency virus by the histone deacetylase inhibitor panobinostat: a pilot study to assess effects on the central nervous system
Thomas A Rasmussen, Martin Tolstrup, Holger Jon Møller, et al.
Plos One
|
May 3, 2013
Administration of a Toll-like receptor 9 agonist decreases the proviral reservoir in virologically suppressed HIV-infected patients
Anni A Winckelmann, Lærke V Munk-Petersen, Thomas A Rasmussen, et al.
Page
of 7